Intravesical Chemotherapy for Superficial Bladder Tumors
Intravesical Chemotherapy for Superficial Bladder Tumors
复制标题
浅表膀胱肿瘤的膀胱内化疗
DOI：
10.1007/978-1-4613-3353-1_13
复制
发表时间：
1982
期刊：
影响因子：
11.2
通讯作者：
C. Schulman
中科院分区：
文献类型：
--
作者：
C. Schulman
浅表性膀胱肿瘤（TNM分期T1、pT1 （UICC, 1974）或Jewett分期0和A）通常采用经尿道切除术（TUR）治疗。然而，大约60%的患者在完全切除后会出现肿瘤复发（8,10,21,22,28），其中很大比例的复发显示出更高的恶性程度（10,22）。10%的病例进展为浸润性癌(8)，TUR后的5年生存率约为62%（8,18,28）。大多数复发肿瘤将在6至12个月内发生。
Superficial bladder tumors (T1, pT1 of the TNM classification (UICC, 1974) or Jewett Stage 0 and A) are usually treated by transurethral resection (TUR). However, recurrence of the tumor after complete resection occurs in about 60% of the patients (8, 10, 21, 22, 28) with a significant percentage of these recurrences showing a higher degree of malignancy (10, 22). In 10% of the cases the tumor progresses to invasive carcinoma (8) and the 5-year survival rate following TUR is about 62% (8, 18, 28). Most of these recurrent tumors will occur within 6 to 12 months.